Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent

NYSE - LSE

RBGPF	-5.85%	71.25	$
RYCEF	0.96%	17.67	$
VOD	0.06%	15.88	$
CMSC	-0.46%	19.63	$
RIO	-1.52%	88.16	$
NGG	2.48%	81.06	$
RELX	0.36%	39.39	$
BTI	1.02%	59.11	$
BCE	1.25%	20.07	$
GSK	2.31%	50.63	$
AZN	2.88%	168.82	$
BP	-0.1%	49.39	$
CMSD	-0.41%	19.69	$
BCC	1.52%	76.28	$
JRI	1.22%	10.63	$

Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent

ECONOMY 15.01.2026

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 15, 2026 / Cell Source, Inc. (OTC Pink Limited:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, announced today that it has closed a private placement of original issue discount convertible notes in the aggregate principal amount of $1,875,000. The Company received gross proceeds of $1,500,000 from the offering. The notes bear interest at a rate of 10% per annum and are convertible into shares of the Company's common stock at a conversion price equal to 90% of the lowest volume weighted average price of the common stock during the ten trading days prior to conversion. The notes become due upon the earlier of June 17, 2026 or the listing of the Company's common stock on the Nasdaq Capital Market or another national securities exchange. For each $100,000 invested, investors in the offering received a five-year warrant to purchase the Company's common stock at an exercise price of $.40 per share. A total of 1,875,000 warrants were issued in the offering.

Text size:

Cell Source is preparing for an uplist to the Nasdaq Capital Market and has engaged Vstock Transfer, LLC as its transfer agent. The Company plans to expand its communications program to share its clinical results and strategic plans going forward.

About Cell Source, Inc.

Cell Source, Inc. is the worldwide, exclusive innovator of Veto Cell-based cellular therapy and immunotherapy platform technologies designed to provide safer and more accessible stem cell (e.g. bone marrow) transplantation and improve the treatment of blood cancers such as leukemia, lymphoma and multiple myeloma. The Company licenses the technology from The Weizmann Institute of Science in Israel and sponsors both research and clinical development projects at a leading US Cancer Center. In addition, its Veto Cell platform is being developed to reverse sickle cell disease and other non-malignant genetic blood disorders and to durably treat auto immune diseases such as type 1 diabetes. The Company is developing a Veto Cell CAR-T platform which could potentially enable CAR-T therapy to be used in donor-derived (allogeneic) settings with increased safety, efficacy, and persistence. Cell Source's Veto Cell technologies are also being developed to facilitate safer, donor mismatched organ transplants (e.g., kidney and liver) and also avoid the current need for life-long daily immune system suppression.

The Company is focused on transitioning this allogeneic Veto Cell platform into additional clinical trials in order to develop safe and curative cell therapy treatments (such as stem cell transplants) from mismatched donors as well as safe, durable, and efficacious "off-the-shelf" immunotherapy and immuno-oncology products.

For more information, visit cell-source.com.

Company Contact

Itamar Shimrat, CEO
646.416.7896
[email protected]

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, inability to meet Nasdaq listing requirements and changes in the general economic climate, as well as the risk factors disclosed in the Company's filings with the Securities and Exchange Common and OTC Markets, Inc. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

SOURCE: Cell Source, Inc.

View the original press release on ACCESS Newswire

A.Williams--AT

Arizona Tribune - Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent

Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent

Featured

As actors get more physical, Bollywood embraces intimacy coordinators

Asian stocks rally as tech firms enjoy bounce ahead of key earnings

Musk backs SpaceX-Tesla merger as rocket firm turns profit

Musk says backs SpaceX-Tesla merger as rocket firm turns profit